Rainer M. Erdtmann

This profile gathers the share dealings of Rainer M. Erdtmann across 3 companies, led by Biomea Fusion, Inc., Pharmacyclics Inc and Polarityte, Inc. Over a trading history stretching from 30 October 2009 to 11 December 2025, the count stands at 44 filings.

In open-market terms, that means 11 purchases worth €3.3M on one side and 6 sales worth €8.8M on the other. The net balance comes to €5.4M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 4 option exercises. 2025 to date brings 3 purchases and no sales.

Half of the purchases are above €43k and half below. On 5 out of 8 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +26.7%. This is a record of the past, not a forecast.

On 15 December 2025 came the latest disclosure, an open-market purchase for €37k in Biomea Fusion, Inc. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.